Pharmacokinetics and Dynamics of Nebulized Dexmedetomidine

Phase

1/2

Condition

Abdominal Cancer

Peritoneal Cancer

Treatment

N/A

Clinical Study ID

NCT03762785

435

Ages 3-7
All Genders

Study Summary

the aim of this study is to study the pharmacokinetics and dynamics of nebulized dexmetedomidine in children undergoing major abdominal cancer surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

child aged 2-7 years
ASA I or II
scheduled for abdominal surgery
with average weight, height, normal serum albumin

Exclusion

Exclusion Criteria:

patients with allergy to the study drug
patients with significant organ dysfunction
patients with cardiac arrhythmia
patients with congenital heart disease
use of psychotropic medication and mental retardation.

Study Design

December 10, 2018

January 31, 2021

Study Description

Inhalation of nebulized drug is an alternative route of administration that is relatively easy to set up, does not require venpuncture, but is associated with high bioavailability of the administered drug. Information on the pharmacokinetics of dexmedetomidine in the pediatric population is very limited, especially in children. To the best of investigators knowledge, there are no published reports on the pharmacokinetics of nebulized dexmedetomidine in children.

Connect with a study center

South Egypt Cancer Institute
Assiut, 11715
Egypt
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.